Pharma channel feed

Re­gen­eron ex­pects key Dupix­ent COPD da­ta this year amid Eylea's sales de­cline in the US

Last year

Mod­er­na looks past post-Covid 'low point' at a fu­ture based on com­bi­na­tion vac­cines, can­cer in­di­ca­tions

Last year

No­vo Nordisk is still play­ing catch up as We­govy de­mand rock­ets up­ward

Last year
Manufacturing

Sarep­ta’s Duchenne gene ther­a­py gets off to a strong start in sales, as fu­ture lies in lim­bo

Last year
Cell/Gene Tx

No­vo Nordisk tem­pers ex­pec­ta­tions for hefty M&A deals as di­a­betes, obe­si­ty sales soar

Last year

Am­gen’s win for a Ste­lara in­ter­change­able biosim­i­lar prompts ques­tions about ‘mean­ing­ful com­pe­ti­tion’ un­der IRA

Last year
FDA+

No­var­tis scores sixth Cosen­tyx ap­proval from FDA, this time to treat hidradeni­tis sup­pu­ra­ti­va

Last year
FDA+

Mer­ck­'s Keytru­da gets bil­iary tract can­cer ap­proval, brings in more pos­i­tive sur­vival da­ta in re­nal car­ci­no­ma

Last year

Ab­b­Vie seeks Resta­sis fol­low-up with small op­tion fee for Aldeyra’s eye drops, de­spite a po­ten­tial 'im­mi­nen­t' CRL

Last year
Deals

Af­ter the ap­plause: New ef­fi­ca­cy ex­pec­ta­tions in urothe­lial can­cer af­ter Pad­cev-Keytru­da da­ta re­veal

Last year
R&D
In Focus

Eli Lil­ly and Boehringer In­gel­heim pay trib­ute to hip-hop an­niver­sary in chron­ic kid­ney dis­ease cam­paign with Rob Base

Last year
Marketing

GSK touts Arexvy sales as it dom­i­nates US old­er adult RSV mar­ket, com­pa­ny cuts three ear­ly-stage as­sets

Last year
R&D

Sanofi en­lists Ush­er, Robin Arzón, Adam Schefter to type 1 di­a­betes ear­ly screen­ing cause

Last year
Marketing

Ap­n­imed and Sh­iono­gi cre­ate $150M joint ven­ture for sleep ap­nea

Last year
Financing
Deals

Up­dat­ed: Eu­ro­pean Com­mis­sion au­tho­rizes No­vavax's up­dat­ed Covid vac­cine

Last year
FDA+
Coronavirus

Nos­trum agrees to $50M set­tle­ment with DOJ over al­le­ga­tions of un­der­pay­ing Med­ic­aid

Last year
Law

Pfiz­er shelves five mid- and ear­ly-stage pro­grams

Last year

FDA push­es can­cer drug de­vel­op­ers to in­clude over­all sur­vival da­ta more fre­quent­ly

Last year
FDA+

GSK steps in for J&J’s li­cense of Ar­row­head’s he­pati­tis B drug, plans com­bo study with its own can­di­date

Last year
Deals
R&D

Mar­ket­ingRx roundup: In­smed, In­cyte rank as top sci­ence work­places; Mod­er­na, Bil­lie Jean King give vac­cine re­minder

Last year
Marketing

Pfiz­er de­tails mR­NA flu vac­cine da­ta, but re­vis­es time­line

Last year

Gala­pa­gos plans to hand over Jy­s­e­le­ca and 400 em­ploy­ees to Al­fasig­ma, re­duce work­force by 100

Last year
People
Deals

Am­gen dis­con­tin­ues prostate can­cer drug in $650M write­down, as obe­si­ty pipeline comes in­to fo­cus in 2024

Last year

Lil­ly makes an­oth­er move for Verve's ge­net­ic med­i­cines, this time buy­ing Beam's opt-in rights

Last year
Deals
Cell/Gene Tx
First page Previous page 92939495969798 Next page Last page
A service from the Financial Times